p53-dependent cell cycle checkpoint pathway (p53 pathway)

The p53-dependent cell cycle checkpoint pathway is a fundamental tumor-suppressive signaling network that monitors genomic integrity and coordinates cellular responses to stress [1.1.1, 1.2.1]. Upon detecting DNA damage, hypoxia, or oncogenic signaling, the p53 transcription factor is stabilized and activated, primarily through the inhibition of its E3 ubiquitin ligase, MDM2 [1.2.1, 1.3.3]. Once active, p53 induces the transcription of various target genes, most notably CDKN1A (encoding p21), which inhibits cyclin-dependent kinases to halt the cell cycle at the G1/S and G2/M checkpoints [1.1.4, 1.2.4]. This arrest provides a window for DNA repair or, in cases of severe damage, triggers permanent senescence or programmed cell death (apoptosis) [1.3.1, 1.4.1]. Dysregulation of this pathway is a hallmark of cancer, occurring through direct TP53 mutations in approximately 50% of human tumors or via the overexpression of negative regulators like MDM2 and MDMX in others [1.1.2, 1.2.3]. Pharmacological intervention aims to reactivate this pathway using MDM2 inhibitors to stabilize wild-type p53 or small-molecule chaperones to restore the functional conformation of mutant p53 [1.1.1, 1.1.2]. Clinical development of these agents faces significant challenges, including dose-limiting hematological toxicities and the emergence of resistance through MDM2/MDMX upregulation or secondary mutations [1.3.1, 1.3.4].

Other names

p53 signaling pathwayp53-mediated cell cycle arrest pathwayp53-dependent G1/S DNA damage checkpointp53-dependent G2/M DNA damage checkpoint

The primary mechanism of action for drugs targeting this pathway involves the restoration of p53 tumor suppressor function. MDM2 inhibitors (e.g., idasanutlin) block the interaction between p53 and its negative regulator MDM2, preventing p53 ubiquitination and degradation, thereby increasing p53 levels to induce cell cycle arrest and apoptosis in wild-type p53 tumors [1.1.1, 1.3.1]. Mutant p53 reactivators (e.g., eprenetapopt) are small molecules that bind to and stabilize the functional conformation of mutated p53, restoring its DNA-binding and transcriptional activity [1.1.1, 1.1.2]. Additionally, inhibitors of upstream kinases such as ATM and ATR (e.g., berzosertib) modulate the DNA damage response to enhance the efficacy of genotoxic therapies or exploit synthetic lethality [1.2.2, 1.4.3].